Unichem Labs anticonvulsant drug Carbamazepine gets USFDA okay
Carbamazepine Tablets are indicated for use as an anticonvulsant drug and in the treatment of the pain associated with true trigeminal neuralgia.
Mumbai: Drugmaker, Unichem Laboratories Limited, has recently announced that the company has received Abbreviated New Drug Application (ANDA) approval for its Carbamazepine Tablets USP, 200 mg from the United States Food and Drug Administration (USFDA).
The medicine is a generic version of TEGRETOL (Carbamazepine) Tablet, 200 mg of Novartis Pharmaceuticals Corp.
Carbamazepine Tablets are indicated for use as an anticonvulsant drug and in the treatment of the pain associated with true trigeminal neuralgia. The product will be commercialized from Unichem's Goa Plant.
Unichem Laboratories Limited is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Next Story
